BRUSSELS—The European Union’s antitrust authority on Friday said it was considering changes to its merger review rules to include a wider swath of technology and pharmaceutical deals that normally wouldn’t fall within its purview but could possibly harm the bloc’s internal market. In a consultation lasting through mid-January of next year, the European Commission said it was fielding opinions from the public on whether the regulator...

Source: Wall Street Journal October 07, 2016 13:30 UTC